Kolexia
Klajer Elodie Oncologie médicale
Klajer Elodie
Oncologie médicale
Hôpital Jean-Minjoz
Besançon, France
53 Activités
6 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs colorectales Carcinome épidermoïde Tumeurs du sein Tumeurs embryonnaires et germinales Tumeurs du testicule Métastase tumorale Seconde tumeur primitive Adénocarcinome

Collaborateurs

Voir plus
Borg Christophe
Borg Christophe
Hôpital Nord Franche-Comté, Montbéliard, France
Vienot Angelique
Vienot Angelique
Le Mittan Annexe Du Hnfc, Montbéliard, France
Orillard Emeline
Orillard Emeline
Hôpital Jean-Minjoz, Besançon, France
Meynard Guillaume
Meynard Guillaume
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
Pfizer
5 collaboration(s)
Dernière en 2023
Servier
3 collaboration(s)
Dernière en 2023
Ipsen
2 collaboration(s)
Dernière en 2020
MSD
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
STARTER: A National, Multicenter, Phase III Randomized Controlled Trial to Assess the Impact of a One-year Supervised Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor Patients
Essai Clinique (Centre Léon-Bérard)   20 février 2024
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Experimental hematology & oncology   21 juillet 2023
P-281 Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023   01 juin 2023
CD8 CD226 T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.
Cellular & molecular immunology   30 janvier 2023
Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma.
Frontiers in oncology   17 novembre 2022
SO-20 Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022, Barcelona, Spain, 29 June -2 July 2022   01 juin 2022
Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients.
Frontiers in oncology   07 mars 2022
509TiP REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
TandHER: Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
Essai Clinique (CHU Besançon)   04 juin 2021
Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.
European journal of cancer (Oxford, England : 1990)   26 mars 2021